Christine Eischen
Faculty Member
Last active: 1/20/2015

Profile

My lab investigates the genes that regulate tumor development. We study the influence tumor suppressors and oncogenes have on apoptosis, proliferation, chromosomal stability, and transformation. We have demonstrated that development to a malignancy is accelerated when there are alterations in the tumor suppressors p53 and ARF, which function to protect cells from hyperproliferative signals from oncogenes, such as Myc. Alternatively, a deficiency in the oncogene Mdm2, which normally inhibits apoptosis, results in the suppression of tumor development. Studies are underway to elucidate novel genes, microRNAs ,and pathways that regulate cellular transformation. Mouse models (knockout and transgenic mice), primary, immortal, and tumor cell cultures, retroviral gene transfer, biochemical purification, and gene chip and proteomic technologies are utilized in our investigations. Results from our studies will provide a better understanding of the genes and pathways that regulate tumorigenesis. Ultimately our studies will lead to a better understanding of cancer development, which will be used for improved therapeutic intervention strategies for human malignancies.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Cell survival is dicey without Dicer. Adams CM, Eischen CM (2014) Mol Cell Oncol 1(2)
    › Primary publication · 25558471 (PubMed) · PMC4279215 (PubMed Central)
  2. Differences in miRNA expression in early stage lung adenocarcinomas that did and did not relapse. Edmonds MD, Eischen CM (2014) PLoS One 9(7): e101802
    › Primary publication · 25028925 (PubMed) · PMC4100742 (PubMed Central)
  3. Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer. Mitra R, Edmonds MD, Sun J, Zhao M, Yu H, Eischen CM, Zhao Z (2014) RNA 20(9): 1356-68
    › Primary publication · 25024357 (PubMed) · PMC4138319 (PubMed Central)
  4. Early changes in miRNA expression are predictive of response to extracorporeal photopheresis in cutaneous T-cell lymphoma. McGirt LY, Baerenwald DA, Vonderheid EC, Eischen CM (2015) J Eur Acad Dermatol Venereol 29(11): 2269-71
    › Primary publication · 24909834 (PubMed) · PMC4831701 (PubMed Central)
  5. MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Grieb BC, Chen X, Eischen CM (2014) Mol Cancer Res 12(9): 1216-24
    › Primary publication · 24866769 (PubMed) · PMC4163510 (PubMed Central)
  6. Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer. Adams CM, Eischen CM (2014) Cancer Res 74(14): 3923-34
    › Primary publication · 24840646 (PubMed) · PMC4104515 (PubMed Central)
  7. Oncogenic protein MTBP interacts with MYC to promote tumorigenesis. Grieb BC, Gramling MW, Arrate MP, Chen X, Beauparlant SL, Haines DS, Xiao H, Eischen CM (2014) Cancer Res 74(13): 3591-602
    › Primary publication · 24786788 (PubMed) · PMC4079748 (PubMed Central)
  8. Mdmx promotes genomic instability independent of p53 and Mdm2. Carrillo AM, Bouska A, Arrate MP, Eischen CM (2015) Oncogene 34(7): 846-56
    › Primary publication · 24608433 (PubMed) · PMC4160436 (PubMed Central)
  9. RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts. Zhang X, Hagen J, Muniz VP, Smith T, Coombs GS, Eischen CM, Mackie DI, Roman DL, Van Rheeden R, Darbro B, Tompkins VS, Quelle DE (2013) PLoS One 8(11): e80228
    › Primary publication · 24282525 (PubMed) · PMC3839920 (PubMed Central)
  10. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis. Sluss HK, Gannon H, Coles AH, Shen Q, Eischen CM, Jones SN (2010) Mol Cancer Res 8(2): 216-22
    › Primary publication · 20145032 (PubMed) · PMC2829875 (PubMed Central)
  11. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Post SM, Quintás-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G (2010) Oncogene 29(9): 1260-9
    › Primary publication · 19935700 (PubMed) · PMC2903442 (PubMed Central)
  12. Murine double minute 2: p53-independent roads lead to genome instability or death. Bouska A, Eischen CM (2009) Trends Biochem Sci 34(6): 279-86
    › Primary publication · 19447627 (PubMed)
  13. The ARF tumor suppressor can promote the progression of some tumors. Humbey O, Pimkina J, Zilfou JT, Jarnik M, Dominguez-Brauer C, Burgess DJ, Eischen CM, Murphy ME (2008) Cancer Res 68(23): 9608-13
    › Primary publication · 19047137 (PubMed) · PMC2637809 (PubMed Central)